πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 81 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12370267

Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)

Northwestern University Β· Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12365711

TGFΞ² signal convertor

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281140

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Enanta Pharmaceuticals, Inc. Β· Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227508

TGF-Ξ² inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215133

GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use

BrightGene Bio-Medical Technology Co., Ltd. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11965032

Anti-CD20 antibody compositions

TG Therapeutics, Inc. Β· Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11958879

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Enanta Pharmaceuticals, Inc. Β· Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884740

Anti-CD20 antibody compositions

TG Therapeutics, Inc. Β· Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11857574

Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG Β· Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11814439

Anti-CD20 antibody compositions

TG Therapeutics, Inc. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11807689

Anti-CD20 antibody compositions

TG Therapeutics, Inc. Β· Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11793816

Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B

Northwestern University Β· Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11718641

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Enanta Pharmaceuticals, Inc. Β· Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11692018

TGF-Ξ² polypeptides

Cue Biopharma, Inc. Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11685775

Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by adm

The Regents of the University of California Β· Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679131

Genetically engineered T cells with regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG Β· Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679130

Genetically engineered t cells with Regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG Β· Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497773

Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved func

CRISPR THERAPEUTICS AG Β· Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11466018

TGF-Ξ² inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11440963

Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352360

TGF-beta inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11236055

Non-systemic TGR5 agonists

VENENUM BIODESIGN, LLC Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11191843

Multi-arm targeting anti-cancer conjugate

BrightGene Bio-Medical Technology Co., Ltd. Β· Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11179467

Exenatide modifier and use thereof

BrightGene Bio-Medical Technology Co., Ltd. Β· Granted Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted